Iovance Biotherapeutics, Inc. (0JDK.L)

USD 3.04

(-7.61%)

Long Term Debt Summary of Iovance Biotherapeutics, Inc.

  • Iovance Biotherapeutics, Inc.'s latest annual long term debt in 2023 was 1 Million USD , down 0.0% from previous year.
  • Iovance Biotherapeutics, Inc.'s latest quarterly long term debt in 2024 Q1 was 1 Million USD , down 0.0% from previous quarter.
  • Iovance Biotherapeutics, Inc. reported annual long term debt of 1 Million USD in 2022, down 0.0% from previous year.
  • Iovance Biotherapeutics, Inc. reported annual long term debt of 1 Million USD in 2021, down -97.8% from previous year.
  • Iovance Biotherapeutics, Inc. reported quarterly long term debt of 1 Million USD for 2024 Q2, down 0.0% from previous quarter.
  • Iovance Biotherapeutics, Inc. reported quarterly long term debt of 1 Million USD for 2023 Q3, down 0.0% from previous quarter.

Annual Long Term Debt Chart of Iovance Biotherapeutics, Inc. (2023 - 2012)

Historical Annual Long Term Debt of Iovance Biotherapeutics, Inc. (2023 - 2012)

Year Long Term Debt Long Term Debt Growth
2023 1 Million USD 0.0%
2022 1 Million USD 0.0%
2021 1 Million USD -97.8%
2020 45.37 Million USD 968.15%
2019 4.24 Million USD 0.0%
2018 - USD 0.0%
2017 - USD 0.0%
2016 - USD 0.0%
2015 - USD 0.0%
2014 - USD 0.0%
2013 - USD 0.0%
2012 - USD 0.0%

Peer Long Term Debt Comparison of Iovance Biotherapeutics, Inc.

Name Long Term Debt Long Term Debt Difference
uniQure N.V. 130.06 Million USD 99.231%
Agios Pharmaceuticals, Inc. 56.98 Million USD 98.245%
Amicus Therapeutics, Inc. 387.85 Million USD 99.742%
Atara Biotherapeutics, Inc. 45.69 Million USD 97.811%
bluebird bio, Inc. 224.41 Million USD 99.554%
Cara Therapeutics, Inc. 37.07 Million USD 97.303%
Imunon, Inc. 1.13 Million USD 12.226%
Editas Medicine, Inc. 24.37 Million USD 95.897%
IQVIA Holdings Inc. 12.95 Billion USD 99.992%
Mettler-Toledo International Inc. 1.97 Billion USD 99.949%
Myriad Genetics, Inc. 130.9 Million USD 99.236%
Neurocrine Biosciences, Inc. 258.3 Million USD 99.613%
Supernus Pharmaceuticals, Inc. 33.19 Million USD 96.988%
Verastem, Inc. 40.08 Million USD 97.505%
Walgreens Boots Alliance, Inc. 8.04 Billion USD 99.988%
Waters Corporation 2.3 Billion USD 99.957%
Thermo Fisher Scientific Inc. 31.3 Billion USD 99.997%
Biogen Inc. 7.18 Billion USD 99.986%
Nektar Therapeutics 112.62 Million USD 99.112%
Perrigo Company plc 3.63 Billion USD 99.972%
Dynavax Technologies Corporation 252.41 Million USD 99.604%
Illumina, Inc. 1.48 Billion USD 99.933%
Corbus Pharmaceuticals Holdings, Inc. 3.23 Million USD 69.123%
Heron Therapeutics, Inc. 173.75 Million USD 99.424%
Unity Biotechnology, Inc. 23.53 Million USD 95.752%
BioMarin Pharmaceutical Inc. 593.09 Million USD 99.831%
Sangamo Therapeutics, Inc. 33.51 Million USD 97.016%
Evolus, Inc. 120.35 Million USD 99.169%
Adicet Bio, Inc. 17.7 Million USD 94.351%
Aclaris Therapeutics, Inc. 3.07 Million USD 67.469%
Regeneron Pharmaceuticals, Inc. 2.7 Billion USD 99.963%
Esperion Therapeutics, Inc. 501.54 Million USD 99.801%
FibroGen, Inc. 89.69 Million USD 98.885%
Agilent Technologies, Inc. 2.73 Billion USD 99.963%
OPKO Health, Inc. 222.03 Million USD 99.55%
Homology Medicines, Inc. 43.17 Million USD 97.684%
Geron Corporation 35.05 Million USD 97.147%
Alnylam Pharmaceuticals, Inc. 2.34 Billion USD 99.957%
Exelixis, Inc. 189.94 Million USD 99.474%
Viking Therapeutics, Inc. 936 Thousand USD -6.838%
Anavex Life Sciences Corp. - USD -Infinity%
Intellia Therapeutics, Inc. 96.74 Million USD 98.966%
Zoetis Inc. 6.56 Billion USD 99.985%
Axsome Therapeutics, Inc. 178.07 Million USD 99.438%
Abeona Therapeutics Inc. 4.4 Million USD 77.283%
Vertex Pharmaceuticals Incorporated 724.7 Million USD 99.862%
Kala Pharmaceuticals, Inc. 34.19 Million USD 97.075%
Ionis Pharmaceuticals, Inc. 1.4 Billion USD 99.929%
Sarepta Therapeutics, Inc. 1.13 Billion USD 99.912%
Corcept Therapeutics Incorporated - USD -Infinity%
Halozyme Therapeutics, Inc. 1.49 Billion USD 99.933%
Blueprint Medicines Corporation 610.96 Million USD 99.836%
Insmed Incorporated 1.19 Billion USD 99.916%
TG Therapeutics, Inc. 100.11 Million USD 99.001%
Incyte Corporation 29.16 Million USD 96.571%
Emergent BioSolutions Inc. 446.5 Million USD 99.776%